NCT00691522TerminatedPhase 2
Open-Label, Imaging Study of Human Corticotropin-Releasing Factor (hCRF) for The Reduction of Peritumoral Brain Edema (PBE) in Patients With Primary Malignant or Metastatic Brain Tumors
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- PharmaNet
- Enrollment
- 60
Study Overview
Brief Summary
This is a phase II, multicenter, open-label, imaging study of hCRF in the reduction of PBE in patients with primary malignant or metastatic brain tumors. Approximately 30 to 60 patients will be assigned to 1 of 3 treatment groups and receive study drug for up to 28 days
Detailed Description
The purpose of this study is to investigate the effect of 3 different regimens of subcutaneous (SC) administered hCRF (1.0 mg every [Q] 8 hours [h], 1.5 mg Q12h, and 1.0 mg Q12h) on the reduction of PBE in patients with primary malignant or metastatic brain tumors as defined by MRI indexes.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •18 years of age or older.
- •Written informed consent has been provided and documented.
- •Primary malignant or metastatic brain tumor that is either asymptomatic or symptomatic patients with the life expectancy estimation of 3 months or more
- •A pretreatment MRI brain scan must identify at least 1 dominant tumor lesion and related PBE that is radiologically (or visibly) distinct from the main tumor mass; the combined tumor-edema lesion must be > 2 cm in longest diameter (for at least 1 slice) and visible in 3 consecutive, 4 mm sections on MRI.
- •No dexamethasone or anti-angiogenic treatment for at least 14 days prior to the Baseline and throughout the study.
- •A Karnofsky Performance Score > 60 at Screening (Visit 1) and at Baseline
- •A negative serum pregnancy test at the Screening (Visit 1) is required for women of childbearing potential.
Exclusion Criteria
- •• Low-grade gliomas, recurrent gliomas, suspected lymphoma, or known human immunosuppressive virus (HIV) infection.
- •Patients requiring surgery, radiosurgery or radiation surgery therapy
- •Patients experiencing severe symptoms related to PBE
- •Patients where MRI is contraindicated for any reason.
- •Signs and/or symptoms of relatively severe cerebral herniation.
- •Concurrent enrollment in any other investigational drug or device study, or plan to enroll in such a study during the 3 to 4 weeks of study treatment.
- •Systemic corticosteroid use (with the exception of inhalers for asthma).
- •Use of dexamethasone (eg, as an anti-emetic) during screening or during the study
- •Use of anti-angiogenic/anti-vascular endothelial growth factor (VEGF) therapy or anticonvulsant therapy (if patient's liver function tests (LFTs) are > 3 times upper limit of normal) 14 days prior to randomization
- •Serious concomitant cardiovascular, pulmonary, renal, gastrointestinal, or endocrine metabolic disease, which in the opinion of the Investigator or the Medical Monitor, would put the patient as unusual risk during study participation.
- •Known renal insufficiency or screening glomerular filtration rate (GFR) < 60 mL/min/1.73 m
- •Central nervous system infection, human immunosuppressive virus (HIV) positive or ongoing infectious process.
- •For female patients: pregnancy, breastfeeding or refusal to practice birth control if of childbearing potential during the study.
- •Inability of the patient to follow the treatment regimen.
- •Known history of methionine allergy.
Investigators
Similar Trials
Completed
Phase 1
A Study of ZL-1211 in Patients With Advanced Solid TumorAdvanced Solid TumorNCT05065710Zai Biopharmaceutical (Suzhou) Co., Ltd.34
Completed
Phase 1
A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT04353102Eucure (Beijing) Biopharma Co., Ltd15
Terminated
Phase 1
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid TumorsSolid TumorNCT05159388Servier Bio-Innovation LLC46
Unknown
Not Applicable
Comparison of Autogenous Dentin Matrix Versus Bovine-Derived Xenograft for Socket PreservationAlveolar Bone ResorptionNCT04239378Krishnadevaraya College of Dental Sciences & Hospital20
Completed
Phase 1
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)Cutaneous T-Cell LymphomaNCT02593045Innate Pharma44